CLINICAL TRIALS PROFILE FOR ACIPHEX
✉ Email this page to a colleague
All Clinical Trials for ACIPHEX
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00204672 ↗ | The Role of GER in Exercise Triggered Asthma | Completed | PriCara, Unit of Ortho-McNeil, Inc. | Phase 2/Phase 3 | 2000-10-01 | HYPOTHESIS Gastroesophageal reflux is a major contributor to exercise-triggered asthma. Two groups of patients will be studied: those with asthma who have difficulty with exertion, those without asthma who experience difficulty with exertion. Both groups will experience gastroesophageal reflux (GER) twice of less per week. Patients will complete a treadmill exam to determine their VO2 max. They will then undergo pH monitoring while exercising for 30 minutes at 65-70% of their VO2 max. Subjects will be given placebo or acid suppression pill for 12 weeks. At the end of 12 weeks, the subjects will repeat the exercise (30 minutes) and 24-hour pH study. |
| NCT00204672 ↗ | The Role of GER in Exercise Triggered Asthma | Completed | University of Utah | Phase 2/Phase 3 | 2000-10-01 | HYPOTHESIS Gastroesophageal reflux is a major contributor to exercise-triggered asthma. Two groups of patients will be studied: those with asthma who have difficulty with exertion, those without asthma who experience difficulty with exertion. Both groups will experience gastroesophageal reflux (GER) twice of less per week. Patients will complete a treadmill exam to determine their VO2 max. They will then undergo pH monitoring while exercising for 30 minutes at 65-70% of their VO2 max. Subjects will be given placebo or acid suppression pill for 12 weeks. At the end of 12 weeks, the subjects will repeat the exercise (30 minutes) and 24-hour pH study. |
| NCT00204698 ↗ | Laryngopharyngeal Reflux and Proton Pump Inhibitor (PPI) Treatment | Completed | PriCara, Unit of Ortho-McNeil, Inc. | Phase 2/Phase 3 | 2003-08-01 | This study proposes to investigate prospectively, the presence of molecular markers for inflammation in laryngopharyngeal reflux (LPR) patients and to study the effect of a proton pump inhibitor (Aciphex) on these molecular markers. The investigators will be evaluating a group of patients before and after treatment. This group will be patients that have untreated laryngopharyngeal reflux diagnosed by laryngoscopic assessment and a 24-hour probe. |
| NCT00204698 ↗ | Laryngopharyngeal Reflux and Proton Pump Inhibitor (PPI) Treatment | Completed | University of Utah | Phase 2/Phase 3 | 2003-08-01 | This study proposes to investigate prospectively, the presence of molecular markers for inflammation in laryngopharyngeal reflux (LPR) patients and to study the effect of a proton pump inhibitor (Aciphex) on these molecular markers. The investigators will be evaluating a group of patients before and after treatment. This group will be patients that have untreated laryngopharyngeal reflux diagnosed by laryngoscopic assessment and a 24-hour probe. |
| NCT00236184 ↗ | E3810-A001-313: Efficacy and Safety of 10 mg Rabeprazole for Treating Heartburn in Frequent Sufferers | Completed | Eisai Inc. | Phase 3 | 2005-10-01 | The purpose of this study is to investigate the safety and efficacy of rabeprazole sodium 10 mg in treating frequent heartburn. |
| NCT00236197 ↗ | E3810-A001-312: Efficacy and Safety of 10 mg Rabeprazole for Treating Heartburn in Frequent Sufferers | Completed | Eisai Inc. | Phase 3 | 2005-10-01 | The purpose of this study is to investigate the safety and efficacy of rabeprazole 10 mg in treating frequent heartburn. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for ACIPHEX
Condition Name
Clinical Trial Locations for ACIPHEX
Trials by Country
Clinical Trial Progress for ACIPHEX
Clinical Trial Phase
Clinical Trial Sponsors for ACIPHEX
Sponsor Name
